- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4 Registration of securities issued in business combination transactions
- 2.2 EX-2.2
- 2.3 EX-2.3
- 2.4 EX-2.4
- 2.5 EX-2.5
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 23.1 EX-23.1
- 23.2 EX-23.2
- 99.3 EX-99.3
- 99.4 EX-99.4
- 99.5 EX-99.5
- 99.6 EX-99.6
- 99.7 EX-99.7
- 99.8 EX-99.8
- 99.9 EX-99.9
- EX-FILING FEES Calculation of Filing Fee Tables
- Download Excel data file
- View Excel data file
- 2 Oct 23 424B3 Prospectus supplement
- 18 Sep 23 424B3 Prospectus supplement
- 6 Sep 23 EFFECT Notice of effectiveness
- 5 Sep 23 424B3 Prospectus supplement
- 5 Sep 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 1 Sep 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 23 Aug 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 26 Jul 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 30 Jun 23 S-4/A Registration of securities issued in business combination transactions (amended)
-
11 May 23 S-4 Registration of securities issued in business combination transactions
- 23 Aug 23 Registration of securities issued in business combination transactions (amended)
- 26 Jul 23 Registration of securities issued in business combination transactions (amended)
- 30 Jun 23 Registration of securities issued in business combination transactions (amended)
- 11 May 23 Registration of securities issued in business combination transactions
Exhibit 99.3
CONSENT OF FINANCIAL ADVISOR
We hereby consent to the inclusion of our opinion letter to the board of directors of Vascular Biogenics, Ltd., as Annex B to the proxy statement/prospectus/information statement which forms a part of the registration statement on Form S-4 originally filed with the Securities and Exchange Commission of the United States (the “Commission”) on even date herewith, and to the references to our firm name, such opinion and the quotation or summarization of such opinion contained therein. Our opinion letter was given as at February 22, 2023 and remains subject to the assumptions, qualifications and limitations contained therein. In providing our consent, we do not intend that any person other than the board of directors of Vascular Biogenics, Ltd. shall be entitled to rely upon our opinion letter.
In giving such consent, we do not admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended (the “Securities Act”), or the rules and regulations of the Commission thereunder, nor do we hereby admit that we are experts with respect to any part of the Registration Statement within the meaning of the term “experts” as used in the Securities Act or the rules and regulations of the Securities and Exchange Commission thereunder.
May 11, 2023
CHARDAN CAPITAL MARKETS LLC